ОЗОН Фармацевтика Financial Statements (OZPH)
|
|
Report date
|
|
|
11.10.2024 |
11.10.2024 |
11.10.2024 |
24.04.2025 |
|
24.04.2025 |
Currency
|
|
|
RUB |
RUB |
RUB |
RUB |
|
RUB |
Financial report URL
|
|
|
|
|
|
|
|
|
|
Drug sales, bln pkg |
|
|
|
|
284.0 |
321.0 |
|
321.0 |
|
Revenue, bln rub |
? |
|
17.7 |
19.0 |
19.7 |
25.6 |
|
25.6 |
Operating Income, bln rub |
|
|
5.44 |
5.50 |
6.15 |
7.94 |
|
7.94 |
EBITDA, bln rub |
? |
|
6.04 |
7.19 |
7.08 |
9.07 |
|
9.07 |
Net profit, bln rub |
? |
|
3.95 |
3.65 |
4.00 |
4.61 |
|
4.61 |
|
OCF, bln rub |
? |
|
2.77 |
-0.994 |
4.66 |
5.83 |
|
5.83 |
CAPEX, bln rub |
? |
|
1.19 |
0.682 |
0.706 |
4.28 |
|
4.28 |
FCF, bln rub |
? |
|
1.26 |
-1.72 |
3.83 |
1.24 |
|
1.24 |
Dividend payout, bln rub
|
|
|
|
|
|
0.197 |
|
0.197 |
|
Dividend, rub/share
|
? |
|
|
|
|
0.18 |
|
0.18 |
Ordinary share dividend yield, %
|
|
|
0.0% |
0.0% |
0.0% |
0.4% |
|
0.3% |
Dividend payout ratio, %
|
|
|
0% |
0% |
0% |
4% |
|
4% |
|
OPEX, bln rub |
|
|
3.44 |
2.28 |
2.40 |
3.11 |
|
3.11 |
Cost of production, bln rub |
|
|
8.86 |
9.48 |
10.8 |
13.9 |
|
13.9 |
Amortization, bln rub |
|
|
0.6 |
0.7 |
0.9 |
1.1 |
|
1.1 |
R&D, bln rub |
|
|
|
|
|
0.325 |
|
0.356 |
Employment expenses, bln rub |
|
|
2.08 |
2.42 |
2.76 |
4.22 |
|
|
Interest expenses, bln rub |
|
|
0.570 |
1.000 |
0.883 |
1.75 |
|
1.75 |
|
Assets, bln rub |
|
|
29.7 |
34.1 |
34.4 |
49.5 |
|
49.5 |
Net Assets, bln rub |
? |
|
12.8 |
14.7 |
16.0 |
25.3 |
|
25.3 |
Debt, bln rub |
|
|
7.91 |
11.4 |
9.26 |
15.5 |
|
15.5 |
Cash, bln rub |
|
|
1.37 |
1.11 |
0.950 |
5.59 |
|
5.59 |
Net debt, bln rub |
|
|
6.53 |
10.3 |
8.31 |
9.94 |
|
9.94 |
|
Ordinary share price, rub |
|
|
35.0 |
35.0 |
35.0 |
41.5 |
|
54.9 |
Number of ordinary shares, mln |
|
|
1 000 |
1 000 |
1 000 |
1 099 |
|
1 099 |
|
Market cap, bln rub |
|
|
35.0 |
35.0 |
35.0 |
45.6 |
|
60.3 |
EV, bln rub |
? |
|
41.5 |
45.3 |
43.3 |
55.5 |
|
70.3 |
Book value, bln rub |
|
|
12.7 |
14.4 |
15.7 |
18.5 |
|
18.5 |
|
EPS, rub |
? |
|
3.95 |
3.65 |
4.00 |
4.20 |
|
4.20 |
FCF/share, rub |
|
|
1.26 |
-1.72 |
3.83 |
1.13 |
|
1.13 |
BV/share, rub |
|
|
12.7 |
14.4 |
15.7 |
16.9 |
|
16.9 |
|
EBITDA margin, % |
? |
|
34.2% |
37.9% |
35.9% |
35.5% |
|
35.5% |
Net margin, % |
? |
|
22.4% |
19.3% |
20.3% |
18.0% |
|
18.0% |
FCF yield, % |
? |
|
3.6% |
-4.9% |
10.9% |
2.7% |
|
2.1% |
ROE, % |
? |
|
30.8% |
24.9% |
25.1% |
18.2% |
|
18.2% |
ROA, % |
? |
|
13.3% |
10.7% |
11.6% |
9.3% |
|
9.3% |
|
P/E |
? |
|
8.87 |
9.58 |
8.74 |
9.88 |
|
13.1 |
P/FCF |
|
|
27.7 |
-20.4 |
9.14 |
36.7 |
|
48.5 |
P/S |
? |
|
1.98 |
1.85 |
1.77 |
1.78 |
|
2.36 |
P/BV |
? |
|
2.76 |
2.42 |
2.23 |
2.46 |
|
3.25 |
EV/EBITDA |
? |
|
6.88 |
6.29 |
6.12 |
6.12 |
|
7.75 |
Debt/EBITDA |
|
|
1.08 |
1.43 |
1.17 |
1.10 |
|
1.10 |
|
Employees, people |
|
|
1 958 |
2 112 |
1 982 |
3 005 |
|
3 005 |
Labour productivity, mln rub/person/year |
|
|
9.01 |
8.98 |
9.95 |
8.51 |
|
8.51 |
Expenses per employee, thousand rub |
|
|
1 060 |
1 145 |
1 391 |
1 404 |
|
0 |
R&D/CAPEX, % |
|
|
0.00% |
0.00% |
0.00% |
7.59% |
|
8.31% |
|
CAPEX/Revenue, % |
|
|
7% |
4% |
4% |
17% |
|
17% |
|
ОЗОН Фармацевтика shareholders |